Neurocrine Biosciences (NBIX) EBT Margin Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1,282.00 |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -491.00 |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 58.00 |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -861.00 |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -1,020.00 |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | -995.00 |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 1,157.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -4,603.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -995.00 |
| Mar 31, 2026 | 5,487.00 |
| Dec 31, 2025 | 110.00 |
| Sep 30, 2025 | 1,147.00 |
| Jun 30, 2025 | 13,970.00 |
| Mar 31, 2025 | -432.00 |
| Dec 31, 2024 | 3,033.00 |
| Sep 30, 2024 | 2,029.00 |
| Jun 30, 2024 | -320.00 |
| Mar 31, 2024 | -480.00 |
| Dec 31, 2023 | 2,165.00 |
| Sep 30, 2023 | 4,526.00 |
| Jun 30, 2023 | -65.00 |
| Mar 31, 2023 | -4,098.00 |
| Dec 31, 2022 | 1,280.00 |
| Sep 30, 2022 | -106.00 |
| Jun 30, 2022 | -14,489.00 |
| Mar 31, 2022 | 8,102.00 |
| Dec 31, 2021 | -1,870.00 |
| Sep 30, 2021 | -2,315.00 |